Peptide Research Library

What Is KLOW Peptide? A Research Guide to the Four-Component Blend

KLOW is a commercial name for a multi-analyte research blend—not a single peptide sequence. This guide explains its four listed components, the exact TB-500 identity used in the blend, and the documentation needed to evaluate a lot.

Last editorial review: July 25, 2026 · Research use only

Research-use-only notice: This page discusses chemical identity, analytical documentation and published experimental literature. It provides no medical advice, dosing, administration or recommendations for human or veterinary use.

What is KLOW peptide?

In BulkGLP’s catalog, KLOW peptide is a lyophilized research blend containing four listed analytes: BPC-157, KPV, TB-500 and GHK-Cu. It is not one molecule with a single sequence or molecular mass. A single-analyte material can be evaluated against one expected identity; a blended material requires researchers to identify and quantify several components in the same sample.

KLOW is also a product name rather than a universally standardized chemical name. Another supplier’s material may use different components, chemical forms, quantities, excipients or testing specifications. Researchers should compare the current product specification with the lot-specific certificate and resolve any analyte-naming discrepancy before treating those records as controlling.

KLOW peptide at a glance

Blend typeFour-component research formulation

Listed componentsBPC-157, KPV, TB-500 and GHK-Cu

TB-500 identity used hereAcetylated fragment, Ac-LKKTETQ-OH

Salt/counterionRequires analyte-specific lot confirmation

The four components have different chemical identities and different evidence bases. Publications about an isolated component do not establish the behavior, interaction or safety of the finished KLOW mixture.

What is in KLOW peptide?

BPC-157

BPC-157 is a synthetic peptide containing 15 amino acids. Cell and animal studies have examined it in models involving endothelial signaling, cell migration and other experimental endpoints. One study using human umbilical-vein endothelial cells reported changes in migration and tube-formation assays under its specific laboratory conditions. The investigators tested BPC-157 alone—not KLOW and not a combination with the other three components. See the primary endothelial-cell study.

That model distinction matters. An observation involving isolated BPC-157 cannot be assigned to the four-component blend. FDA’s current scientific review also describes limited human evidence and unresolved safety and characterization questions. Read FDA’s BPC-157 evaluation.

KPV

KPV is the tripeptide Lys-Pro-Val, corresponding to the C-terminal three-residue sequence of alpha-melanocyte-stimulating hormone. A primary Gastroenterology study evaluated PepT1-mediated uptake and signaling endpoints in cell and animal models. It did not evaluate the branded KLOW formulation. See the primary KPV/PepT1 study.

Chemical form should remain attached to the identity. KPV free base and KPV acetate are not interchangeable descriptions. FDA’s review distinguishes the forms and reports that it found no clinical studies or human-exposure data for KPV. See FDA’s KPV evaluation.

TB-500: the short thymosin-beta-4 fragment

BulkGLP identifies the intended KLOW component as TB-500: the N-terminally acetylated seven-amino-acid fragment Ac-LKKTETQ-OH, corresponding to human thymosin beta-4 residues 17–23. PubChem and FDA reference records list the parent/free-base substance as C38H68N10O14 with a molecular weight of about 889.0 g/mol. Those reference values describe that chemical record; they do not establish the counterion or salt form of a specific BulkGLP lot. See the PubChem TB-500 identity record and FDA’s TB-500 chemistry evaluation.

Identity distinction: TB-500 in this blend is the seven-residue fragment Ac-LKKTETQ-OH. It is not full-length thymosin beta-4, which contains 43 amino acids. Findings generated with the full-length peptide cannot automatically be attributed to TB-500.

A primary HPLC/high-resolution-mass-spectrometry investigation identified and synthesized Ac-LKKTETQ in TB-500. See the primary analytical-identification paper. The WADA-sponsored analytical project provides additional context.

Salt form changes the formula and formula weight. FDA lists TB-500 acetate separately from the parent/free-base record. The current legacy KLOW report uses the broader analyte label “Thymosin Beta-4” and does not identify the TB-500 counterion or salt form. It therefore needs an analyte-specific clarification or revised report before any lot-specific formula or molecular weight is stated.

GHK-Cu

GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine. Primary fibroblast studies measured collagen synthesis and matrix-metalloproteinase expression after GHK-Cu exposure under controlled in-vitro conditions. Those experiments support component-level research questions, but they neither test the KLOW blend nor establish a human outcome. See the primary collagen-synthesis study and primary fibroblast MMP study.

GHK peptide, copper ions and GHK-Cu should not be treated as interchangeable analyte names. The exact complex, stoichiometry, counterion and analytical reference belong in the applicable product and lot records.

Why study a multi-component peptide blend?

A multi-component formulation can support an experiment designed around the mixture as a whole. It may also be useful for multi-analyte method development or for comparing a blended condition with matched single-component controls.

The tradeoff is attribution. If an assay response changes after exposure to KLOW, the blend alone cannot show which component contributed, whether the measured quantities were equivalent across conditions or whether an interaction occurred. A defensible design may include the vehicle, the complete blend, each component separately and planned combination controls. “Synergy” is a conclusion requiring an appropriate quantitative design; it should not be assumed from a product name or from separate component papers.

What should a KLOW COA show?

A useful lot-specific evidence set should let a laboratory answer the following questions:

Lot identity: Do the vial, product record and laboratory report reference the same lot?
Analyte identity: Is each expected component supported by an appropriate mass-identification result?
Chemical form: Are free base, acetate, peptide fragment and metal complex described accurately?
Measured content: Is each analyte quantified rather than represented only by a nominal total?
Chromatographic purity: Is the reported percentage explained for a multi-analyte sample?
Additional tests: If endotoxin or other tests are reported, are the method, threshold and sample result shown?

HPLC provides a chromatographic profile. LC-MS can support identity through detected mass. Quantitative content addresses how much analyte was measured. These results characterize the submitted sample; they do not prove clinical safety, sterility for administration, therapeutic effectiveness or regulatory approval.

Review BulkGLP’s published lot-specific peptide COAs together with the KLOW four-component research-blend specification. The product and COA should use the same TB-500 fragment identity.

KLOW vs Glow peptide: the short answer

BulkGLP’s KLOW blend lists four components, while Glow lists three. Both list BPC-157, the short TB-500 fragment and GHK-Cu. KLOW additionally lists KPV. That fourth analyte changes the composition and the controls needed for a comparison; it does not by itself make one formulation stronger or better.

Read the full KLOW vs Glow peptide research comparison for a component-by-component breakdown.

Research-use limitation

KLOW and its listed components are supplied for controlled laboratory research only. They are not approved for human or veterinary administration. This page provides no dosing, injection, treatment or clinical-use instructions. Component-level preclinical findings should not be represented as proven properties of the finished blend.

Frequently asked questions

Is KLOW a single peptide?

No. In BulkGLP’s catalog, KLOW is a four-component research blend rather than one peptide sequence.

What peptides are listed in KLOW?

The current formulation lists BPC-157, KPV, the short TB-500 fragment and GHK-Cu. The matching lot COA should confirm each identity, form and measured content.

Is TB-500 the same as thymosin beta-4?

No. TB-500 here is the acetylated seven-residue fragment Ac-LKKTETQ-OH. Full-length thymosin beta-4 contains 43 amino acids.

What is the difference between KLOW and Glow?

The two BulkGLP blends share BPC-157, TB-500 and GHK-Cu. KLOW additionally lists KPV.

Is the KLOW formula standardized across suppliers?

No. KLOW is a commercial blend name. Confirm the analytes, chemical forms, quantities, excipients and lot documentation for the specific material being studied.

Does one purity percentage confirm every component amount?

No. Chromatographic purity and quantitative content are different measurements. A blend should have identity and measured-content evidence for each analyte.

Is KLOW approved for human use?

No. BulkGLP supplies KLOW strictly as a laboratory research material, not for human or veterinary administration.

Primary and authoritative references

Continue with the peptide COA verification guide, review laboratory peptide storage and handling, or view the KLOW research-blend specification.